Search
Avita is working towards FDA approval of its ReCell technology in the US.

Avita sells respiratory business

Perth-based regenerative medicine company Avita Medical says it will be able to focus more on its core ReCell technology after completing the sale of its respiratory business for $2.47 million.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Top 10 Shareholders

Substantial shareholders as published in the annual report.
Source: Morningstar

Total Shareholder Return as at 30/09/19

1 year TSR5 year TSR
8thAvita Medical462%47%
733 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

10/01/19
$0 Other
10/01/19
$0 Other
10/01/19
$15k Bought
Total value as at the date of the transaction
Source: Morningstar

Revenue

th-Avita Medical$17.0m
77 listed non wa companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer